This bill aims to significantly restrict the availability and use of mifepristone for abortion. A key provision mandates that, 14 days after the bill's enactment, the Food and Drug Administration's approval for mifepristone (marketed as Mifeprex or RU-486) for the termination of intrauterine pregnancy will be deemed withdrawn . Consequently, the introduction or delivery of mifepristone into interstate commerce for this indication would constitute a violation of the Federal Food, Drug, and Cosmetic Act, and the drug would be considered misbranded if its labeling suggests such use. Furthermore, the legislation establishes a new federal tort , effective 90 days after enactment, creating liability for manufacturers of mifepristone. This provision allows any individual who suffers bodily injury or harm to mental health attributable to the use of mifepristone to bring a civil action against the manufacturer. Such actions can seek compensatory damages, punitive damages, and attorney's fees and costs, without preempting any existing state laws that offer additional remedies.